Therapeutic potential of TIM-3 inhibition in cancer, viral infections, and autoimmune disorders
Authors:
- 1 July 2025
- journal article
- review article
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 186, 106826
Abstract
No abstract availableKeywords
Funding Information
- Canadian Institutes of Health Research
- NSERC
This publication has 91 references indexed in Scilit:
- Arf1 Ablation in Colorectal Cancer Cells Activates a Super Signal Complex in DC to Enhance Anti‐Tumor ImmunityAdvanced Science, 2023
- TIM-3 as a promising target for cancer immunotherapy in a wide range of tumorsCancer Immunology, Immunotherapy, 2023
- Identification of a novel small-molecule inhibitor targeting TIM-3 for cancer immunotherapyBiochemical Pharmacology, 2023
- The biologically functional identification of a novel TIM3-binding peptide P26 in vitro and in vivoCancer Chemotherapy and Pharmacology, 2020
- Tim3+ Foxp3 + Treg Cells Are Potent Inhibitors of Effector T Cells and Are Suppressed in Rheumatoid ArthritisInflammation, 2017
- Expression of human T cell immunoglobulin domain and mucin-3 (TIM-3) and TIM-3 ligands in peripheral blood from patients with systemic lupus erythematosusArchives of Dermatological Research, 2016
- Immunophenotyping of Cerebrospinal Fluid Cells in Multiple SclerosisJAMA Neurology, 2014
- T‐bet, a Th1 transcription factor regulates the expression of Tim‐3European Journal of Immunology, 2010
- Tumor-derived microvesicles modulate the establishment of metastatic melanoma in a phosphatidylserine-dependent mannerCancer Letters, 2009
- B lymphocyte and macrophage expression of carcinoembryonic antigen‐related adhesion molecules that serve as receptors for murine coronavirusEuropean Journal of Immunology, 1994